Top Markets
#1 Helium Helium +93.49%
#2 MowCat MowCat +84.25%
#3 Seeker Seeker +49.37%
#4 UnifAI Network UnifAI Network +32.18%
#5 TENDIES TENDIES +30.27%
#6 Pons Pons +24.00%
#7 Zylo Ecosystem Zylo Ecosystem +22.28%
#8 Bounce Bounce +18.04%
#9 Tensor Tensor +17.67%
#10 Zora Zora +16.77%
Coin of the day
Helium Helium
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CHO Pharma, Inc. CHO Pharma, Inc.

CHO Pharma, Inc.

6586
Classifica tra le azioni #11104
CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan,... CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan, specializes in the research and development of innovative therapeutic solutions. Central to its operations is an advanced glycoengineering platform. This proprietary technology facilitates the creation of several key therapeutic modalities, including SAR-based glycoengineered "biobetters," site-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines designed to target unique carbohydrate antigens. The company also offers CHOptimax, an innovative in vitro enzymatic single-step process. This technology allows for the precise transformation of unconjugated antibodies into either glycoengineered biobetters or ADCs. CHO Pharma boasts a robust and diverse pipeline of drug candidates spanning various therapeutic areas, all leveraging its glycoengineering expertise. Currently, several programs are in clinical development: CHO-H01 is undergoing Phase I/IIa trials for refractory non-Hodgkin lymphoma, while CHO-A04, a humanized monoclonal antibody, has entered Phase I trials targeting a range of tumor and cancer stem cells. Additionally, CHO-V08 is being developed as a vaccine against Klebsiella pneumoniae. In the preclinical stage, CHO Pharma is advancing CHO-H02, an agent designed to address various solid tumors including breast, bladder, pancreatic, ovarian, and gastric cancers. Another preclinical asset, CHO-H03, is an antibody drug being investigated for inflammatory conditions associated with autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Established in 2012, CHO Pharma continues to innovate from its base in Taipei City, Taiwan.
Prezzo delle azioni
$3.47
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$741.78M
Variazione (1 giorno)
-0.91%
Variazione (1 anno)
181.14%
Paese
TW
Scambia CHO Pharma, Inc. (6586)

Categoria

Healthcare
Storico dividendi per CHO Pharma, Inc. (6586)
CHO Pharma, Inc. (simbolo azionario: 6586) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per CHO Pharma, Inc. (6586) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH